The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

NEW YORK (Reuters) -U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which ...

Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session.

Recent data reveals that the eurozone economy has narrowly skirted a recession, showing lukewarm yet positive growth. With ...